Top

Published in:

01-08-2020 | Cytostatic Therapy | Original Article

Characterization of CD103⁺ CD8⁺ tissue-resident T cells in esophageal squamous cell carcinoma: may be tumor reactive and resurrected by anti-PD-1 blockade

Authors: Lu Han, Quan-Li Gao, Xiu-Man Zhou, Chao Shi, Guan-Yu Chen, Yong-Ping Song, Yong-Jie Yao, Yu-Miao Zhao, Xue-Yan Wen, Shi-Lei Liu, Yuan-Ming Qi, Yan-Feng Gao

Published in: Cancer Immunology, Immunotherapy | Issue 8/2020

Abstract

Though therapy that promotes anti-tumor response about CD8⁺ tumor-infiltrating lymphocytes (TILs) has shown great potential, clinical responses to CD8⁺ TILs immunotherapy vary considerably, largely because of different subpopulation of CD8⁺ TILs exhibiting different biological characters. To define the relationship between subpopulation of CD8⁺ TILs and the outcome of antitumor reaction, the phenotype and function of CD103⁺ CD8⁺ TILs in esophageal squamous cell carcinoma (ESCC) were investigated. CD103⁺ CD8⁺ TILs were presented in ESCC, which displayed phenotype of tissue-resident memory T cells and exhibited high expression of immune checkpoints (PD-1, TIM-3). CD103⁺ CD8⁺ TILs were positively associated with the overall survivals of ESCC patients. This population of cells elicited potent proliferation and cytotoxic cytokine secretion potential. In addition, CD103⁺ CD8⁺ TILs were elicited potent anti-tumor immunity after anti-PD-1 blockade and were not affected by chemotherapy. This study emphasized the feature of CD103⁺ CD8⁺ TILs in immune response and identified potentially new targets in ESCC patients.

Available only for authorised users

Rustgi AK, El-Serag HB (2014) Esophageal carcinoma. N Engl J Med 371(26):2499–2509. https://doi.org/10.1056/NEJMra1314530 CrossRefPubMed

Stoner GD, Gupta A (2001) Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis 22(11):1737–1746. https://doi.org/10.1093/carcin/22.11.1737 CrossRefPubMed

Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, Bashir N, Bridgewater JA, Geh JI, Cunningham D, Blazeby J, Roy R, Maughan T, Griffiths G (2013) Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol 14(7):627–637. https://doi.org/10.1016/s1470-2045(13)70136-0 CrossRefPubMed

van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, Henegouwen MIV, Wijnhoven BPL, Richel DJ, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, ten Kate FJW, Creemers GJ, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A, Grp C (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084. https://doi.org/10.1056/Nejmoa1112088 CrossRefPubMed

Mariette C, Piessen G, Triboulet JP (2007) Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 8(6):545–553. https://doi.org/10.1016/s1470-2045(07)70172-9 CrossRefPubMed

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–386. https://doi.org/10.1002/ijc.29210 CrossRefPubMed

Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. https://doi.org/10.1038/nrc3239 CrossRefPubMedPubMedCentral

Drake CG, Lipson EJ, Brahmer JR (2014) Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 11(1):24–37. https://doi.org/10.1038/nrclinonc.2013.208 CrossRefPubMed

Kono K, Mimura K, Yamada R, Ujiie D, Hayase S, Tada T, Hanayama H, Min AKT, Shibata M, Momma T, Saze Z, Ohki S (2018) Current status of cancer immunotherapy for esophageal squamous cell carcinoma. Esophagus 15(1):1–9. https://doi.org/10.1007/s10388-017-0596-2 CrossRefPubMed

10.

Kojima T, Doi T (2017) Immunotherapy for esophageal squamous cell carcinoma. Curr Oncol Rep 19(5):33. https://doi.org/10.1007/s11912-017-0590-9 CrossRefPubMedPubMedCentral

11.

Hirano H, Kato K (2019) Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy. Jpn J Clin Oncol 49(5):412–420. https://doi.org/10.1093/jjco/hyz034 CrossRefPubMed

12.

Atreya I, Neurath MF (2008) Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies. Expert Rev Anticancer Ther 8(4):561–572. https://doi.org/10.1586/14737140.8.4.561 CrossRefPubMed

13.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964. https://doi.org/10.1126/science.1129139 CrossRefPubMed

14.

Ganesan AP, Clarke J, Wood O, Garrido-Martin EM (2017) Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat Immunol 18(8):940–950. https://doi.org/10.1038/ni.3775 CrossRefPubMedPubMedCentral

15.

Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, Rosenberg SA (2014) PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Investig 124(5):2246–2259. https://doi.org/10.1172/JCI73639 CrossRefPubMed

16.

Mackay LK, Rahimpour A, Ma JZ, Collins N, Stock AT, Hafon ML, Vega-Ramos J, Lauzurica P, Mueller SN, Stefanovic T, Tscharke DC, Heath WR, Inouye M, Carbone FR, Gebhardt T (2013) The developmental pathway for CD103(+)CD8(+) tissue-resident memory T cells of skin. Nat Immunol 14(12):1294–1301. https://doi.org/10.1038/ni.2744 CrossRefPubMed

17.

Mueller SN, Gebhardt T, Carbone FR, Heath WR (2013) Memory T cell subsets, migration patterns, and tissue residence. Annu Rev Immunol 31:137–161. https://doi.org/10.1146/annurev-immunol-032712-095954 CrossRefPubMed

18.

Gebhardt T, Mueller SN, Heath WR, Carbone FR (2013) Peripheral tissue surveillance and residency by memory T cells. Trends Immunol 34(1):27–32. https://doi.org/10.1016/j.it.2012.08.008 CrossRefPubMed

19.

Carbone FR, Mackay LK, Heath WR, Gebhardt T (2013) Distinct resident and recirculating memory T cell subsets in non-lymphoid tissues. Curr Opin Immunol 25(3):329–333. https://doi.org/10.1016/j.coi.2013.05.007 CrossRefPubMed

20.

Beura LK, Masopust D (2014) SnapShot: resident memory T cells. Cell 157(6):1488–1488.e1481. https://doi.org/10.1016/j.cell.2014.05.026 CrossRefPubMed

21.

Mueller SN, Mackay LK (2016) Tissue-resident memory T cells: local specialists in immune defence. Nat Rev Immunol 16(2):79–89. https://doi.org/10.1038/nri.2015.3 CrossRefPubMed

22.

Schenkel JM, Masopust D (2014) Tissue-resident memory T cells. Immunity 41(6):886–897. https://doi.org/10.1016/j.immuni.2014.12.007 CrossRefPubMedPubMedCentral

23.

Kaech SM, Wherry EJ, Ahmed R (2002) Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2(4):251–262. https://doi.org/10.1038/nri778 CrossRefPubMed

24.

Wakim LM, Woodward-Davis A, Liu R, Hu YF, Villadangos J, Smyth G, Bevan MJ (2012) The molecular signature of tissue resident memory CD8 T cells isolated from the brain. J Immunol 189(7):3462–3471. https://doi.org/10.4049/jimmunol.1201305 CrossRefPubMed

25.

Quinn E, Hawkins N, Yip YL, Suter C, Ward R (2003) CD103(+) intraepithelial lymphocytes—a unique population in microsatellite unstable sporadic colorectal cancer. Eur J Cancer 39(4):469–475. https://doi.org/10.1016/s0959-8049(02)00633-0 CrossRefPubMed

26.

Cresswell J, Robertson H, Neal DE, Griffiths TRL, Kirby JA (2001) Distribution of lymphocytes of the alpha(E)beta(7) phenotype and E-cadherin in normal human urothelium and bladder carcinomas. Clin Exp Immunol 126(3):397–402. https://doi.org/10.1046/j.1365-2249.2001.01652.x CrossRefPubMedPubMedCentral

27.

Ling KL, Dulphy N, Bahl P, Salio M, Maskell K, Piris J, Warren BF, George BD, Mortensen NJ, Cerundolo V (2007) Modulation of CD103 expression on human colon carcinoma-specific CTL. J Immunol 178(5):2908–2915. https://doi.org/10.4049/jimmunol.178.5.2908 CrossRefPubMed

28.

Webb JR, Wick DA, Nielsen JS, Tran E, Milne K, McMurtrie E, Nelson BH (2010) Profound elevation of CD8⁺ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer. Gynecol Oncol 118(3):228–236. https://doi.org/10.1016/j.ygyno.2010.05.016 CrossRefPubMed

29.

French JJ, Cresswell J, Wong WK, Seymour K, Charnley RM, Kirby JA (2002) T cell adhesion and cytolysis of pancreatic cancer cells: a role for E-cadherin in immunotherapy? Br J Cancer 87(9):1034–1041. https://doi.org/10.1038/sj.bjc.6600597 CrossRefPubMedPubMedCentral

30.

Reichenbach ZW, Murray MG, Saxena R, Farkas D, Karassik EG, Klochkova A, Patel K, Tice C, Hall TM, Gang J, Parkman HP, Ward SJ, Tetreault MP, Whelan KA (2019) Clinical and translational advances in esophageal squamous cell carcinoma. Adv Cancer Res 144:95–135. https://doi.org/10.1016/bs.acr.2019.05.004 CrossRefPubMed

31.

Kelly RJ (2019) The emerging role of immunotherapy for esophageal cancer. Curr Opin Gastroenterol. https://doi.org/10.1097/MOG.0000000000000542 CrossRefPubMed

32.

Mokrani M, Klibi J, Bluteau D, Bismuth G, Mami-Chouaib F (2014) Smad and NFAT pathways cooperate to induce CD103 expression in human CD8 T lymphocytes. J Immunol 192(5):2471–2479. https://doi.org/10.4049/jimmunol.1302192 CrossRefPubMed

33.

Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA, Wherry EJ (2009) Coregulation of CD8⁺ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10(1):29–37. https://doi.org/10.1038/ni.1679 CrossRefPubMed

34.

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330. https://doi.org/10.1056/NEJMoa1412082 CrossRefPubMed

35.

Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, Goodall CP, Blair TC, Fox BA, McDermott JE, Chang SC, Grunkemeier G, Leidner R, Bell RB, Weinberg AD (2018) Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. https://doi.org/10.1038/s41467-018-05072-0 CrossRefPubMedPubMedCentral

36.

Webb JR, Milne K, Nelson BH (2014) Location, location, location CD103 demarcates intraepithelial, prognostically favorable CD8(+) tumor-infiltrating lymphocytes in ovarian cancer. Oncoimmunology. https://doi.org/10.4161/onci.27668 CrossRefPubMedPubMedCentral

37.

Workel HH, Komdeur FL, Wouters MCA, Plat A, Klip HG, Eggink FA, Wisman GBA, Arts HJG, Oonk MHM, Mourits MJE, Yigit R, Versluis M, Duiker EW, Hollema H, de Bruyn M, Nijman HW (2016) CD103 defines intraepithelial CD8⁺ PD1⁺ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. Eur J Cancer 60:1–11. https://doi.org/10.1016/j.ejca.2016.02.026 CrossRefPubMed

38.

Chang WC, Li CH, Huang SC, Chang DY, Chou LY, Sheu BC (2010) Clinical significance of regulatory T cells and CD8(+) effector populations in patients with human endometrial carcinoma. Cancer 116(24):5777–5788. https://doi.org/10.1002/cncr.25371 CrossRefPubMed

39.

Kondratiev S, Sabo E, Yakirevich E, Lavie O, Resnick MB (2004) Intratumoral CD8(+) T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res 10(13):4450–4456. https://doi.org/10.1158/1078-0432.CCR-0732-3 CrossRefPubMed

40.

de Jong RA, Leffers N, Boezen HM, ten Hoor KA, van der Zee AGJ, Hollema H, Nijman HW (2009) Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol 114(1):105–110. https://doi.org/10.1016/j.ygyno.2009.03.022 CrossRefPubMed

41.

Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833. https://doi.org/10.1056/NEJMoa1606774 CrossRef

42.

Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, Hironaka S, Hara H, Satoh T, Iwasa S, Muro K, Yasui H, Minashi K, Yamaguchi K, Ohtsu A, Doki Y, Kitagawa Y (2017) Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol 18(5):631–639. https://doi.org/10.1016/S1470-2045(17)30181-X CrossRefPubMed

43.

Cook AM, Lesterhuis WJ, Nowak AK, Lake RA (2016) Chemotherapy and immunotherapy: mapping the road ahead. Curr Opin Immunol 39:23–29. https://doi.org/10.1016/j.coi.2015.12.003 CrossRefPubMed

44.

Brown JS, Sundar R, Lopez J (2018) Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. Br J Cancer 118(3):312–324. https://doi.org/10.1038/bjc.2017.376 CrossRefPubMed

45.

Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G (2015) Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28(6):690–714. https://doi.org/10.1016/j.ccell.2015.10.012 CrossRefPubMed

46.

Wang W, Kryczek I, Dostal L, Lin H, Tan L, Zhao L, Lu F, Wei S, Maj T, Peng D, He G, Vatan L, Szeliga W, Kuick R, Kotarski J, Tarkowski R, Dou Y, Rattan R, Munkarah A, Liu JR, Zou W (2016) Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer. Cell 165(5):1092–1105. https://doi.org/10.1016/j.cell.2016.04.009 CrossRefPubMedPubMedCentral

Title: Characterization of CD103+ CD8+ tissue-resident T cells in esophageal squamous cell carcinoma: may be tumor reactive and resurrected by anti-PD-1 blockade
Authors: Lu Han
Quan-Li Gao
Xiu-Man Zhou
Chao Shi
Guan-Yu Chen
Yong-Ping Song
Yong-Jie Yao
Yu-Miao Zhao
Xue-Yan Wen
Shi-Lei Liu
Yuan-Ming Qi
Yan-Feng Gao
Publication date: 01-08-2020
Publisher: Springer Berlin Heidelberg
Keyword: Cytostatic Therapy
Published in: Cancer Immunology, Immunotherapy / Issue 8/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02562-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2020

Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment

Epstein–Barr virus (EBV) and polyomaviruses are detectable in oropharyngeal cancer and EBV may have prognostic impact

Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients

Characterising the prognostic potential of HLA-DR during colorectal cancer development

Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade

Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial

Keynote webinar | Spotlight on antibody–drug conjugates in cancer